CClinicalTrials.gg
RecruitingNCT06880861IMPACTUpdated Oct 2, 2026

Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers

An observational study in Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Mayo Clinic · Observational

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.

02

Conditions studied

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm

Keywords

  • cancer
  • adolescent
  • young adult
  • cognition
  • memory
  • exercise
  • physical activity
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 150 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with primary diagnosis of cancer when 15-39 years old.

Inclusion criteria

  • Adults (aged 18+ years)
  • Primary diagnosis of cancer when 15-39 years-old
  • Access to a desktop computer or laptop with reliable internet access
  • No gross motor impairments that prohibit ambulation
  • Willing to complete study requirements
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with nonmelanoma skin cancer only
  • Not diagnosed with cancer in adolescent and young adult (AYA) age range of 15-39 years
  • Scheduled travel during the study period that is not indicative of individual's normal schedule
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)

Groups and cohorts

  • Observational

    Patients complete questionnaires and cognitive tasks and wear an activity monitor to measure physical activity on study. Some patients may optionally participate in an interview on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-Interventional Study

06

What researchers measure

Primary outcomes

  1. Cognitive performance on Stroop task

    Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Cognitive performance on Visual Memory Test

    Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.

    Time frame: 2 weeks

  2. Cognitive performance on Verbal Memory Test

    Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.

    Time frame: 2 weeks

  3. Cognitive performance on Symbol Digit Coding Test

    Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.

    Time frame: 2 weeks

  4. Cognitive performance on Shifting Attention Test

    Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.

    Time frame: 2 weeks

  5. Cognitive performance on Continuous Performance Test

    Assessed using the CNS Vital Signs computerized testing platform ("brain games").

    Time frame: Up to 4 weeks

  6. Cognitive performance on Reasoning Test

    Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.

    Time frame: 2 weeks

  7. Cognitive performance on Four Part Continuous Performance Test

    Assessed using the CNS Vital Signs computerized testing platform ("brain games"). CNS Vital Signs is a computerized neuropsychological/neurocognitive assessment platform used by clinicians and researchers to objectively evaluate brain function and neurocognitive status, offering a range of tests and tools for assessment and management of various neurological and behavioral conditions.

    Time frame: 2 weeks

  8. Self-reported cognition - FACT-COG

    Evaluated using the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG), a 37-item questionnaire assessing cognitive impairment, cognitive abilities, and quality of life over the past 7 days. Responses are on a 5-point scale (Never; About once a week; Two to three times a week; Nearly every day; Several times a day). Higher scores generally indicate better self-reported cognition.

    Time frame: 2 weeks

  9. Average weekly minutes of physical activity

    Moderate-to-vigorous physical activity (MVPA) will be measured using an accelerometer (activPAL) which participants will wear on their non-dominant thigh for 7 consecutive days.

    Time frame: 2 weeks

07

Study locations

1 of 1 sites recruiting
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified, limited datasets will be shared with other researchers upon request or according to journal publication requirements

Supporting information: Study protocol

09

Updates

1 registry update since Sep 25, 2026
Primary completion
Sep 30, 2026→Dec 15, 2026
Oct 2, 2026
Study completion
Sep 30, 2026→Dec 15, 2026
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Sep 30, 2026→Dec 15, 2026
    Study completion Sep 30, 2026→Dec 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06880861
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Jul 1, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Melissa Cole
Contact
mailto:ARZENL@mayo.edu
480-574-4052
Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Diane K. Ehlers, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion